Opioid Kullanım Bozukluğu Olan Hastalarda Gabapentin ve Pregabalin Kullanım Sıklığı

Yıl 2022, Cilt: 23 Sayı: 2, 139 - 144, 30.06.2022

Erdinç Çiçek , Başak Demirel

https://doi.org/10.51982/bagimli.978693

Cited By: 1

Öz

Amaç: Bu çalışmanın amacı AMATEM polikliniğine opioid kullanımı nedeniyle başvuran hastalarda gabapentin ve pregabalin kullanım sıklığının araştırılmasıdır.
Yöntem: Çalışmaya halen opioid kullanan veya buprenorfin/ naloksan tedavisi alan 144 opioid kullanım bozukluğu olan hasta alındı.Yarı yapılandırılmış görüşme protokolü ile opioid ve gabapentinoid kullanımları değerlendirildi.
Bulgular:Yaşam boyu gabapentin ve pregabalin kullanım sıklığı sırasıyla %51,4 ve %50,7 olarak bulundu. Polikliniğe başvurduğu sırada hastaların %35,4’ü gabapentin, %26,4’ü pregabalin kullanıyordu. Buprenorfin/naloksan kullanan hastaların %46’sının hem pregabalin hem de gabapentin kullandığı bulundu. Folyo ile opioid kullanan hastalar ile damardan kullanan hastalar arasında gabapentinoid kullanım sıklığı arasında herhangi bir fark bulunmadı.
Sonuç: Opioid kullanım öyküsü olan hastaların gabapentinoid kötüye kullanımı için yüksek riskli bir grup oluşturduğu görülmektedir. Opioid kullanan hastaları takip eden hekimlerin kötüye kullanma riski olan hastalarda gabapentinoid reçete ederken dikkatli olmaları ve hastalara gabapentinoidlere alternatif ilaçlar önermeleri uygun olabilir.

Anahtar Kelimeler

Gabapentin, Pregabalin, Opioid

Destekleyen Kurum

yok

Proje Numarası

yok

Teşekkür

yok

Prevalence of Gabapentin and Pregabalin Use in Patients with Opioid Use Disorder

Öz

Objective: The aim of this study is to investigate the frequency of use of gabapentin and pregabalin in patients who applied to the AMATEM outpatient clinic for opioid use.
Method: The study included one hundred forty-four patients with opioid use disorder who were currently using opioids or were receiving buprenorphine/naloxone treatment. Opioid and gabapentinoid use were evaluated with a semi-structured interview protocol.
Results: The lifetime prevalence of gabapentin and pregabalin use was 51.4% and 50.7%, respectively. At the time of admission to the outpatient clinic, 35.4% of the patients were using gabapentin and 26.4% were using pregabalin. 46% of the patients using buprenorphine/naloxone used both pregabalin and gabapentin. There was no difference in the frequency of gabapentinoid use between the patients using opioids with foil and the patients using IV opioids.
Conclusion: Patients with a history of opioid use appear to constitute a high-risk group for gabapentinoid abuse. It may be appropriate for physicians following patients using opioids to be careful while prescribing gabapentinoids for patients at risk of abuse and to recommend alternative drugs to gabapentinoids.

Anahtar Kelimeler

Gabapentin, pregabalin, opioid

Proje Numarası

yok

Kaynakça

• Referans1. Calandre EP, Rico-Villademoros F, Slim M. Alpha2delta ligands, gabapentin, pregabalin and mirogabalin: a review of their clinical pharmacology and therapeutic use. Expert review of neurotherapeutics. 2016;16(11):1263-77.
• Referans2. Tassone DM, Boyce E, Guyer J, Nuzum D. Pregabalin: a novel γ-aminobutyric acid analogue in the treatment of neuropathic pain, partial-onset seizures, and anxiety disorders. Clin Ther. 2007;29(1):26-48.
• Referans3. Mersfelder TL, Nichols WH. Gabapentin: abuse, dependence, and withdrawal. Ann Pharmacother. 2016;50(3):229-33.
• Referans4. Papazisis G, Tzachanis D. Pregabalin's abuse potential: a mini review focusing on the pharmacological profile. Int J Clin Pharmacol Ther. 2014;52(8):709-16.
• Referans5. Schjerning O, Rosenzweig M, Pottegård A, Damkier P, et al. Abuse potential of pregabalin. CNS drugs. 2016;30(1):9-25.
• Referans6. Grosshans M, Lemenager T, Vollmert C, Kaemmerer N, et al. Pregabalin abuse among opiate addicted patients. European journal of clinical pharmacology. 2013;69(12):2021-5.
• Referans7. Smith RV, Lofwall MR, Havens JR. Abuse and diversion of gabapentin among nonmedical prescription opioid users in Appalachian Kentucky. American Journal of Psychiatry. 2015;172(5):487-8.
• Referans8. Bastiaens L, Galus J, Mazur C. Abuse of gabapentin is associated with opioid addiction. Psychiatric Quarterly. 2016;87(4):763-7.
• Referans9. Kapil V, Green JL, Le Lait M-C, Wood DM, et al. Misuse of the γ-aminobutyric acid analogues baclofen, gabapentin and pregabalin in the UK. British journal of clinical pharmacology. 2014;78(1):190.
• Referans10. Evoy KE, Morrison MD, Saklad SR. Abuse and misuse of pregabalin and gabapentin. Drugs. 2017;77(4):403-26.
• Referans11. Dahlman D, Abrahamsson T, Kral AH, Hakansson A. Nonmedical use of antihistaminergic anxiolytics and other prescription drugs among persons with opioid dependence. Journal of addiction. 2016;2016.
• Referans12. Sason A, Adelson M, Schreiber S, Peles E. Pregabalin misuse in methadone maintenance treatment patients in Israel: Prevalence and risk factors. Drug and alcohol dependence. 2018;189:8-11.
• Referans13. Wagner E, Raabe F, Martin G, Winter C, et al. Concomitant drug abuse of opioid dependent patients in maintenance treatment detected with a multi‐target screening of oral fluid. The American journal on addictions. 2018;27(5):407-12.
• Referans14. Snellgrove BJ, Steinert T, Jaeger S. Pregabalin use among users of illicit drugs: a cross-sectional survey in Southern Germany. CNS drugs. 2017;31(10):891-8.
• Referans15. Lyndon A, Audrey S, Wells C, Burnell ES, et al. Risk to heroin users of polydrug use of pregabalin or gabapentin. Addiction. 2017;112(9):1580-9.
• Referans16. Vickers Smith R, Boland EM, Young AM, Lofwall MR, et al. A qualitative analysis of gabapentin misuse and diversion among people who use drugs in Appalachian Kentucky. Psychology of Addictive Behaviors. 2018;32(1):115.
• Referans17. Chatterjee A, Lopez D, Ramkellawan S, Brown R, et al. “That’s what we call the cocktail”: non-opioid medication and supplement misuse among opioid users. Substance abuse. 2021;42(2):175-82.
• Referans18. Piralishvili G, Gamkrelidze I, Nikolaishvili N, Chavchanidze M. Needs assessment and treatment compliance at state opioid substitution treatment programes in Georgia. Georgian Med News. 2013;214:28-32.
• Referans19. Heikman P, Sundström M, Pelander A, Ojanperä I. New psychoactive substances as part of polydrug abuse within opioid maintenance treatment revealed by comprehensive high‐resolution mass spectrometric urine drug screening. Human Psychopharmacology: Clinical and Experimental. 2016;31(1):44-52.
• Referans20. Evoy K. E, Sadrameli S, Contreras J. Covvey, J. R, et al. Abuse and misuse of pregabalin and gabapentin: a systematic review update. Drugs. 2020; 1-32. Referans21. Buttram ME, Kurtz SP. Descriptions of gabapentin misuse and associated behaviors among a sample of opioid (Mis) users in South Florida. Journal of Psychoactive Drugs. 2021;53(1):47-54.
• Referans22. Bonnet U, Scherbaum N. How addictive are gabapentin and pregabalin? A systematic review. European neuropsychopharmacology. 2017; 27 (12): 1185-1215.
• Referans23. Driot D, Chicoulaa B, Jouanjus E, Dupouy J, et al. Pregabalin use disorder and secondary nicotine dependence in a woman with no substance abuse history. Therapies. 2016;71(6):575-8.
• Referans24. Buttram ME, Kurtz SP, Dart RC, Margolin ZR. Law enforcement‐derived data on gabapentin diversion and misuse, 2002‐2015: diversion rates and qualitative research findings. Pharmacoepidemiology and drug safety. 2017;26(9):1083-6.
• Referans25. Schifano F, D’Offizi S, Piccione M, Corazza O, et al. Is there a recreational misuse potential for pregabalin? Analysis of anecdotal online reports in comparison with related gabapentin and clonazepam data. Psychotherapy and psychosomatics. 2011;80(2):118-22.